Post-earnings recap
Reported
Tue, Feb 15, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, CRISPR Therapeutics' stock rose by 4.03%, indicating investor optimism or relief following the earnings report. The lack of revenue details and guidance may leave some investors cautious, but the stock's positive reaction suggests confidence in the company's long-term potential. The management's focus on R&D could be a key factor in future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.84 | N/A | -6.05% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current challenges but highlighted their commitment to advancing their research. However, they did not provide any new guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts in research and development.
There were no specific updates on future projects or timelines.